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prior to transplantation induced down-regulation of the costimu-
latory molecules CD40, CD80 and CD86 and MHC class II on
recipient APCs and enhanced the protective statin effect when
donor and recipient were treated (survival AT vs PBS, p0.0012).
Induction of the Th-2 cytokine proﬁle was still permissive for in
vivo graft vs leukemia effects by cytolytic effector function of
CD8 T cells against A20 B-cell lymphoma cells as assessed by
bioluminescence imaging, histology and survival. In vitro CD8 T
cells derived from AT treated animals displayed equal cytolytic
activity against Yac1 T-cell lymphoma cells as compared to T cells
derived from PBS treated animals. Mechanistically we identiﬁed a
role for the STAT-6 pathway in statin induced Th-2 induction as
aGvHD protection was partially reversed with STAT-6-/- donors.
Since L-mevalonate produced by the HMG-CoA reductase is the
precursor of non steroidal isoprenoid compounds, such as farnesyl
and geranylgeranyl pyrophosphate, the statin impact on prenyla-
tion status of critical signaling proteins in alloreactive T cells was
determined. In vitro AT treatment reduced the levels of RAP-1,
RhoB and Ras prenylation in allo-antigen exposed T cells and
abrogated expression of T-bet which is critical for Th1 induction.
We conclude that type II statins have signiﬁcant protective impact
on aGvHD lethality by Th-2 cytokine induction and inhibition of
an uncontrolled Th-1 response, without reduction of GvL activity
which is of great clinical relevance given the widespread use and
well deﬁned toxicity proﬁle of these agents.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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OUTCOMES OF DOUBLE CORD BLOOD TRANSPLANTATION (DCBT) IN A
DIVERSE POPULATION
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Petz, L.8, Chow, R.8,9,10 1Massachusetts General Hospital, Boston, MA;
2City of Hope National Medical Center, Duarte, CA; 3University of
Arizona Medical Center, Tucson, AZ; 4Chang Gung Children’s Hospital
& University, Linkou, Taiwan; 5Mount Elizabeth Hospital, Singapore;
6Cook Children’s Hospital, Fort Worth, TX; 7UCLA School of Public
Health, Los Angeles, CA; 8StemCyte International Cord Blood Center,
Arcadia, CA; 9StemCyte Taiwan National Cord Blood Center, Linkou,
Taiwan; 10StemCyte Research Institute, Arcadia, CA.
Cord blood is an alternative stem cell source for patients, but
single cord blood units (CBU) may not contain sufﬁcient cell dose
for cord blood transplantation of adults. Double cord blood trans-
plantation (DCBT) has been used to increase the cell dose, but the
majority of reported patients have been Caucasian. We conducted
a retrospective analysis of 43 consecutive DCBT recipients who
received at least one cord blood unit from the StemCyte cord
blood banks. The median age was 21 years (range 1-59) and the
median weight was 59 kg (range 11-112). Diagnoses were: 14
AML, 9 ALL, 6 CML, 5 Thalassemia, 2 Myelodysplasia, 1 lym-
phoma, 1 aplastic anemia and 5 others. 54% were advanced risk,
26% standard risk, and 20% unknown risk status for the leukemia/
lymphoma/MDS cases. Sixty seven percent of the recipients were
non-Caucasian&em;15 patients were Asian, 14 Caucasian, 4 Native
American, 3 Hispanic, 3 African American, 1 mixed race and 3
unknown. Patients were treated with a variety of conditioning
regimens (28% reduced intensity) at 21 international centers over
4 continents. 19 patients received 2 plasma depleted cord blood
units. Cord unit characteristics were as follows: median pre-freeze
TNC dose 3.4  107/kg, median pre-freeze CD34 dose 1.1 
105/kg. The median time to neutrophil (ANC500) engraftment
was 22 days and the median time to platelet 20K and 50K engraft-
ment were 45 days and 62 days respectively. Kaplan-Meier esti-
mates of 1-year transplant related mortality, overall survival, and
disease free survival were 37%, 49%, and 44 % respectively.
Causes of death include infection (33%), multi-organ failure
(21%), relapse (17%), GvHD (0%), and other (29%). Engraftment
correlated with cell dose and disease risk status in univariate anal-
ysis. In conclusion, 1) Double cord blood transplantation can be
performed effectively in a racially diverse patient population, 2)
Plasma depleted cord blood units can be used safely, 3) Cell counts
remain important for engraftment even with the use of 2 cord
blood units.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION WITH RE-
DUCED INTENSITY CONDITIONING AND SIROLIMUS-BASED GVHD
PROPHYLAXIS
Cutler, C.1, Haspel, R.2, Kao, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1,
Dey, B.2, Spitzer, T.2, Soiffer, R.J.1, Antin, J.H.1, Ballen, K.1 1Dana-
Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital,
Boston, MA.
Umbilical cord blood (UCB) is an alternative for patients without
related or unrelated donors. Single-unit UCB transplantation in
adults is associated with high transplant related mortality, largely due
to delayed engraftment and infection, so we studied the value of
double unit umbilical cord blood (DUCB) transplantation.Methods:
Reduced-intensity conditioning consisted of ﬂudarabine 30mg/m2 x 6
days, melphalan 100mg/m2 x 1 day, and rabbit ATG 1.5 mg/kg x 4
days. DUCB units were 4/6 HLA-A, B, DR1 matched with each
other and the recipient, and contained a minimum combined dose of
3.7  107 TNC/kg (pre-cryopreservation). GVHD prophylaxis con-
sisted of tacrolimus (serum conc. 5-10 ng/ml) and sirolimus (serum
conc. 3-12 ng/ml), which is effective in PBSC transplantation. Re-
sults: 18 patients (median age 48.5 years, range 19-64) with100 day
follow-up are reported. Diagnoses include NHL(6), AML(5),
MDS(3), HD(3), and CML(1). The total cell doses infused were
4.23 107 TNC/kg (range 3.51–6.74 107) and 2.11 105 CD34
cells/kg (range 0.48–5.67 105). Subjects engrafted neutrophils at 22
(median, range 15–75) and platelets at 46 (median, range 24-69) days
from transplantation. Two subjects did not attain platelet transfusion
independence and there was 1 late graft failure. 100-day treatment-
related mortality was 16.7%. 3 patients developed Gr II-IV acute
GVHD (2 Gr. II and 1 Gr. III) and 2 patients developed chronic
GVHD at a median of 30 and 203 days from transplantation respec-
tively. The median follow up is 6.5 months (range 3-12 months) and
overall survival at 1 year is 64.3%. Causes of death include sepsis(4),
relapse(1), and EBV-associated PTLD(1). Chimerism analysis (n14)
at day 30 revealed complete single cord chimerism in 3, mixed cord
chimerism in 10, and persistent host hematopoiesis with single or
double cord chimerism in 1. By day 100, 5/9 patients demonstrated
complete single cord chimerism and 3/9 demonstrated persistent
double cord chimerism. Conclusions: This study demonstrates ex-
cellent engraftment after DUCB transplantation in adult recipients
after a reduced-intensity conditioning regimen. Using sirolimus and
tacrolimus as GVHD prophylaxis, the risk of acute and chronic
GVHD is low when compared to our prior experience with cyclo-
sporine and MMF, and survival is comparable to other unrelated
donor cohorts. Long-term follow-up on an expanded patient cohort
will be presented at ASBMT.
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EFFECT OF CD3 CELL DOSE ON OUTCOME IN PATIENTS AFTER
CONDITIONING INCLUDING ANTITHYMOCYTE GLOBULIN FOLLOWED
BY UN-MANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD
AND MARROW TRANSPLANTATION
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We investigated the potential correlation between the character-
istics prior transplantation and the subsequent clinical outcomes in
175 consecutive patients who received HSC transplantation from
HLA-mismatched/haploidentical donors. Patients eligible for
study were those with a diagnosis of leukemia, all lacking an HLA
matched sibling or unrelated donor. Patients ranged in age from 6
to 53 years (median 25 years) and donors from 13 to 66 years
(median 40 years). Compatibility testing of family members in-
cluded serology and intermediate resolution DNA typing for
HLA-A, -B, and -C antigens, plus high resolution DNA typing for
HLA-DRB1, -DQB1, and -DPB1. Donors included 72 mothers
(41%), 29 fathers (16.6%), 54 siblings (31%), 16 children (9%), 4
cousins (2.3%), with various grades of HLA disparity: 28 (16%)
with 1; 79 (45%) with 2; 68 (39%) with 3 antigen mismatch. Grafts
(BMPB) was harvested from donor BM collected after four days
of G-CSF, and PB collected after 5 days of G-CSF. The graft was
analyzed for content of CD34 cells and subsets of lymphoid cell
populations, CD3, CD4, CD8, and CD14, using standard-
ized Multi-set kits (Becton-Dickinson, San Jose, CA, USA). All
patients enrolled in this study were treated with a uniform condi-
tioning regimen (BuCy2ATG), given GVHD prophylaxis
(CsA short term MTX), and followed from 36 to 1191days after
transplantation (median 401 days). Univariate analysis for survival
indicated that disease status prior transplantation and donor CD3
cell dose were the only predictors of the 2-year probability of
survival: early disease (77.8%), intermediate disease (38%), and
those with advanced disease (52%), [P0.018]; survival in those
given a CD3 cell dose 150 106/kg was 52% and CD3 cell
dose 150106/kg was 74%, respectively [P0.0215]. This was
conﬁrmed by multivariate analysis: patients transplanted with in-
termediate/advanced stage disease [RR1.568 (95% CI, 1.128-
2.17); P0.007] had a worse overall survival; Infusion of a high
dose of CD3 cells (150  106/kg) had improved survival [0.530
(0.300-0.95); P0.03] without increase the incidence of developing
Grade 3-4 aGVHD [1.27 (0.58-2.76); P0.56]. Our data have
indicated that with the current protocol, patients given a relatively
high dose of CD3 cells (150106/kg) have a signiﬁcantly better
overall survival after transplantation than those given lower doses
of CD3 cells (150 106/kg).
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HLA-DRB1 ALLELE AND DRB1-DQB1 HAPLOTYPE FREQUENCY AS PRE-
DICTION CRITERION FOR THE DURATION OF AN UNRELATED BLOOD
STEM CELL DONOR SEARCH
Mytilineos, J.1, Hirv, K.1 1Department of Transplantation Immunology,
Institute for Clinical Transfusion Medicin and Immunogenetics, Ulm
University Hospital, Ulm, Baden-Wu¨rttemberg, Germany.
Identiﬁcation of at least one fully compatible unrelated blood
stem cell donor requires conﬁrmatory typing (CT) of 2-5 poten-
tially matched donors. We developed an algorithm, based on the
frequency of the HLA-DRB1 alleles and the estimated DRB1-
DQB1 haplotypes of the patient, which deﬁned the number of
potentially matched donors requested for CT. This strategy aimed
to result to a shorter UDS duration as well as to cost-effectiveness
in the process of a Unrelated donor search (UDS).
HLA-DRB1 allele frequencies were calculated based on the Na-
tional Marrow Donor Program dataset of 65752 individuals. HLA-
DRB1-DQB1 haplotype data were obtained from the German
National Donor Registry (ZKRD). HLA-DRB1 allele frequencies
within a given broad allele family (e.g. HLA-DRB1*11) were the
main point of consideration, since for most donors only a low
resolution typing was available. HLA-DRB1 alleles with a fre-
quency of 80-100% within their broad allele family were consid-
ered as very frequent. Alleles with a frequency of 30-79% within
their broad allele family as average, and a frequency of 0-29% as
rare. In addition, if the association of a particular HLA-DRB1
allele with the corresponding HLA- DQB1 allele was more fre-
quent than 80%, this DRB1-DQB1 haplotype was considered as
very common. A haplotype corresponding to 20% to 79% of a
given DRB1 allele was classiﬁed as average, whereas a haplotype
frequency of lower than 20% of a particular DRB1 allele was
considered as rare. Based on this algorithm, the probability to ﬁnd
a fully compatible donor for a patient was considered high, me-
dium or low. For the patients with high, medium or low probabil-
ity, three, 4 or 5 potentially matched unrelated donors were re-
quested for CT at the beginning of a UDS, respectively.
In a group of 794 patients, the average duration of UDS and the
average number of identiﬁed donors has been calculated. Eighty
percent of the searches showed a high, 7% a medium and 13% a
low probability to ﬁnd a fully compatible donor. The average UDS
duration was 55, 105, and 135 days in the three groups, respec-
tively. An average of 2.0, 1.6, and 1.0 donors were found in the
groups with high, medium, and low probability, respectively.
The algorithm used in our search unit, allows a prediction of
UDS duration and the estimation of the UDS success rate. A
variable number of potentially matched donors should be re-
quested for CT, which allows economising the UDS process with-
out prolongation of the UDS duration.
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TIVE CONDITIONING IN ADULT PATIENTS WITH ACUTE MYELOID
LEUKEMIA NOT IN REMISSION
Ooi, J.1, Takahashi, S.1, Tomonari, A.1, Tojo, A.1, Asano, S.1 1Depart-
ment of Hematology and Oncology, Institute of Medical Science, Univer-
sity of Tokyo, Tokyo, Japan.
Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute myeloid leukemia (AML) not in re-
mission, a suitably matched related donor is unavailable for ap-
proximately two-thirds of patients. Recently, umbilical cord blood
from unrelated donors have been used as an alternative stem cell
source for adult patients with AML. Here, we report our clinical
results of unrelated cord blood transplantation (CBT) after my-
eloablative conditioning for 30 adult patients with AML not in
remission. Between August 1998 and November 2005, 30 adult
patients with AML not in remission were treated with unrelated
CBT at The Institute of Medical Science, University of Tokyo.
Diagnoses at transplantation included de novo AML (n14) and
MDS-related secondary AML (n16). All patients received four
fractionated 12 Gy total body irradiation and chemotherapy as
myeloablative conditioning. 27 patients received standard cyclo-
sporine (CyA) and methotrexate, and 3 patients received CyA only
as a graft-versus-host disease (GVHD) prophylaxis. Among the
patients the median age was 45.5 years (range, 19-55 years), the
median weight was 55 kg (range, 36-76 kg) and the median number
of cryopreserved nucleated cells was 2.43  107/kg (range, 1.16-
5.29  107/kg). 28 patients had myeloid reconstitution and the
median time to more than 0.5  109/L absolute neutrophil count
was 21.5 days. A self-sustained platelet count more than 50 
109/L was achieved in 23 patients at a median time of 42 days.
Acute GVHD above grade II occurred in 15 of 28 evaluable
patients and chronic GVHD occurred in 17 of 23 evaluable pa-
tients. Among 17 chronic GVHD patients, 7 patients were exten-
sive type. 16 patients are alive and free of disease at between 280
and 2937 days after transplantation. With a median follow-up of
2013 days, the probability of disease-free survival at 5 years was
51.8%. These results suggest that adult patients with AML not in
remission should be considered as candidates for CBT.
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